Oak Hill Bio
Summary active Updated Jun 6, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Oak Hill Bio is a Cambridge, Massachusetts-based biotechnology company advancing rugonersen, an investigational antisense oligonucleotide (ASO) therapy for the treatment of Angelman syndrome 12. Rugonersen was originally developed at Roche; several former members of the program joined Oak Hill Bio to lead its continued development 1. Proceeds from the Series A will be used to advance rugonersen into a pivotal Phase 3 clinical study, expected to begin in mid-2026 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-01 | Series A | $32.5M | Balyasny Asset Management, venBio, Janus Henderson Investors | KCap Biotechnology Fund 12 |
What Investors Say
No independently sourced investor quotes beyond press release boilerplate are available at this time. In connection with the financing, Doug Fambrough (founder of KCap Biotechnology Fund), Rich Gaster (Managing Partner at venBio), and Sandeep Kulkarni (CEO of Zura Bio) joined the Oak Hill Bio board of directors 1.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
“Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome,” GlobeNewswire, June 1, 2026. Accessed June 2026. https://www.globenewswire.com/news-release/2026/06/01/3304351/0/en/oak-hill-bio-raises-32-5-million-series-a-financing-to-advance-antisense-oligonucleotide-therapy-rugonersen-to-phase-3-study-in-angelman-syndrome.html↩↩↩↩↩
-
“Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome,” BioSpace, June 1, 2026. Accessed June 2026. https://www.biospace.com/press-releases/oak-hill-bio-raises-32-5-million-series-a-financing-to-advance-antisense-oligonucleotide-therapy-rugonersen-to-phase-3-study-in-angelman-syndrome↩↩↩